| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H26I6N2O10 |
| Molecular Weight | 1287.9189 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=C(I)C=C(I)C(NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C1I
InChI
InChIKey=WWVAPFRKZMUPHZ-UHFFFAOYSA-N
InChI=1S/C26H26I6N2O10/c27-13-11-15(29)23(21(31)19(13)25(37)38)33-17(35)1-3-41-5-7-43-9-10-44-8-6-42-4-2-18(36)34-24-16(30)12-14(28)20(22(24)32)26(39)40/h11-12H,1-10H2,(H,33,35)(H,34,36)(H,37,38)(H,39,40)
| Molecular Formula | C26H26I6N2O10 |
| Molecular Weight | 1287.9189 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Sourcing
PubMed
Sample Use Guides
A total of 90 patients were given an intravenous injection of
20 ml of 40%
meglumine iodoxamate (iodoxamic acid) containing 183 mg/mI of organically bound
iodine. The 20 ml dose was given intravenously over a 10 mm
interval.
Route of Administration:
Intravenous
